Cognition Therapeutics, Inc. (CGTX)

NASDAQ: CGTX · IEX Real-Time Price · USD
1.92
+0.11 (6.08%)
Oct 4, 2022 4:00 PM EDT - Market closed
6.08%
Market Cap 43.60M
Revenue (ttm) n/a
Net Income (ttm) -22.10M
Shares Out 22.71M
EPS (ttm) -1.80
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 74,018
Open 1.81
Previous Close 1.81
Day's Range 1.75 - 1.98
52-Week Range 1.50 - 13.80
Beta n/a
Analysts Buy
Price Target 14.62 (+661.5%)
Earnings Date Aug 10, 2022

About CGTX

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of de... [Read more...]

Industry Biotechnology
IPO Date Oct 8, 2021
Employees 19
Stock Exchange NASDAQ
Ticker Symbol CGTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for CGTX stock is "Buy." The 12-month stock price forecast is 14.62, which is an increase of 661.46% from the latest price.

Price Target
$14.62
(661.46% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Cognition Therapeutics to Participate in the 2022 Cantor Fitzgerald Neurology & Psychiatry Conference

PURCHASE, N.Y., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”), a clinical-stage biopharmaceutical company engaged in the discovery and dev...

5 days ago - GlobeNewsWire

Cognition Therapeutics Awarded $2.14 Million in Supplemental Grant Funding from NIA to Support SEQUEL Clinical Trial

PURCHASE, N.Y., Sept. 27, 2022 (GLOBE NEWSWIRE) --  Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced today that the company has received a $2.14M grant award from the National Institute on Aging (N...

1 week ago - GlobeNewsWire

Cognition Therapeutics Announces Participation in September Investment Conferences

PURCHASE, N.Y., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”), a clinical-stage biopharmaceutical company engaged in the discovery and dev...

4 weeks ago - GlobeNewsWire

Cognition Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

Ongoing Patient Dosing in SHIMMER Study for DLB and SHINE Study for Alzheimer's Disease Positive Preliminary Data for Dry AMD Program Presented at ARVO 2022 Proteomics Data from SPARC read out at AAIC

1 month ago - GlobeNewsWire

Cognition Therapeutics Presents New Proteomic Data on Effect of CT1812 Treatment on Normalization of Disrupted Alzhei...

Presented at Alzheimer's Association International Conference August 4, 2022 Presented at Alzheimer's Association International Conference August 4, 2022

2 months ago - GlobeNewsWire

Cognition Therapeutics Presenting New Analyses from Ongoing Clinical Trial of CT1812 in Mild-to-Moderate Alzheimer's ...

- Analyses Demonstrate CT1812 Impact on Alzheimer's Disease Processes -

2 months ago - GlobeNewsWire

Cognition Therapeutics Doses First Patient with Dementia with Lewy Bodies in Phase 2 Clinical Study of CT1812

- Study Supported by $30M NIA Grant Award and Conducted in Collaboration with University of Miami Miller School of Medicine and the Lewy Body Dementia Association -

3 months ago - GlobeNewsWire

Cognition Therapeutics Announces Presentation at the Upcoming JMP Securities Life Sciences Conference

PURCHASE, N.Y., June 08, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced that the company will participate in the JMP Securities Life Sciences Conference on June 16th. Lis...

3 months ago - GlobeNewsWire

Cognition Therapeutics to Host Virtual KOL Symposium on Dry Age-related Macular Degeneration and the Potential for Si...

Taking place on June 9 at 10:00 a.m. ET Taking place on June 9 at 10:00 a.m. ET

4 months ago - GlobeNewsWire

Cognition Therapeutics to Participate in H.C. Wainwright Global Investment Conference

PURCHASE, N.Y., May 13, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing therapies that treat age-related degenerative diseases of t...

4 months ago - GlobeNewsWire

Cognition Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

Treatment Commences in Second Cohort of Phase 2 SHINE Study in Mild-to-Moderate Alzheimer's Disease

4 months ago - GlobeNewsWire

CORRECTION -- Cognition Therapeutics to Report First Quarter 2022 Financial Results on May 11, 2022

PURCHASE, N.Y., May 04, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Cognition Therapeutics, Inc. (NASDAQ: CGTX), please note that in the first paragraph of the ...

5 months ago - GlobeNewsWire

Cognition Therapeutics to Report First Quarter 2022 Financial Results on May 11, 2022

PURCHASE, N.Y., May 04, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage neuroscience company developing therapies that treat age-related degenerative diseases of t...

5 months ago - GlobeNewsWire

Cognition Therapeutics to Present Preclinical Results Demonstrating Therapeutic Potential for Sigma-2 Receptor Modula...

NEW YORK, April 25, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics , Inc. (NASDAQ: CGTX), a clinical stage neuroscience company developing drugs that treat age-related degenerative diseases of the cent...

5 months ago - GlobeNewsWire

Cognition Therapeutics Announces Participation in B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference

PURCHASE, N.Y., April 25, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage neuroscience company developing drugs to treat age-related degenerative diseases of the c...

5 months ago - GlobeNewsWire

Cognition Therapeutics Announces Participation in 21st Annual Needham Virtual Healthcare Conference

PURCHASE, N.Y., April 06, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage neuroscience company developing drugs to treat age-related degenerative diseases of the c...

5 months ago - GlobeNewsWire

Cognition Therapeutics Reports Year End 2021 Financial Results and Provides Business Update

- Well capitalized from $52 million IPO and $169 million in grant funding - - Established clinical program in Alzheimer's disease enhanced by new DLB study and dry AMD program - - Conference call and li...

6 months ago - GlobeNewsWire

Cognition Therapeutics to Present Analyses from Clinical Studies of CT1812 in Patients with Alzheimer's Disease at AD...

NEW YORK, March 10, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics , Inc. (NASDAQ: CGTX), a clinical stage neuroscience company developing drugs that treat age-related degenerative diseases of the cent...

6 months ago - GlobeNewsWire

Cognition Therapeutics to Participate in Panel during the BIO CEO & Investor Conference on the Development of Neurode...

Anthony Caggiano, M.D., Ph.D., Participating on February 15th Panel: “Exploring the Possibilities of Developing Neurodegenerative Therapeutics” Anthony Caggiano, M.D., Ph.D., Participating on February 1...

7 months ago - GlobeNewsWire

Cognition Therapeutics Provides Update on Corporate and Pipeline Progress and Reviews Goals for 2022

PURCHASE, N.Y., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small mo...

8 months ago - GlobeNewsWire

Cognition Therapeutics to Participate in Next-Generation Alzheimer's Disease Panel at Virtual Biotech Showcase on Jan...

Lisa Ricciardi, CEO, to participate as a Panelist in, “Aduhelm: Stimulating the Next- Generation of AD Treatment” Lisa Ricciardi, CEO, to participate as a Panelist in, “Aduhelm: Stimulating the Next- Ge...

9 months ago - GlobeNewsWire

Cognition Therapeutics to Host Virtual R&D Symposium December 7 on Dementia with Lewy Bodies and the Potential for Si...

PURCHASE, N.Y., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small mo...

10 months ago - GlobeNewsWire

Cognition Therapeutics Reports Third Quarter Financial Results and Company Highlights

Capital from upsized IPO plus substantial NIA grants supports clinical progress of novel small-molecule σ-2 modulators into new indications Capital from upsized IPO plus substantial NIA grants supports ...

10 months ago - GlobeNewsWire

3 Companies That Went Public Last Month

Are these IPOs right for you?

Other symbols: GTLBPTLO
11 months ago - The Motley Fool

Pittsburgh Life Sciences Greenhouse Proudly Announces IPO of Portfolio Company Cognition Therapeutics

PITTSBURGH, Oct. 12, 2021 /PRNewswire/ --  Pittsburgh Life Science Greenhouse (PLSG) is proud to share that one of its portfolio companies, Cognition Therapeutics, Inc., launched an initial public offer...

11 months ago - PRNewsWire